Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

[1]  S. Han,et al.  Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015 , 2017, Emerging infectious diseases.

[2]  K. Han,et al.  Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar , 2017, Malaria Journal.

[3]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[4]  Zbynek Bozdech,et al.  Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Nicholas P. J. Day,et al.  Genomic epidemiology of artemisinin resistant malaria. , 2016, eLife.

[6]  A. Hughes,et al.  Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  M. Fay,et al.  Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. , 2016, The Lancet. Infectious diseases.

[8]  J. Arrese,et al.  A one-year survey of Microsporum audouinii infections in Belgium: epidemiological and genotypic characterization. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  K. Chotivanich,et al.  K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar , 2016, Malaria Journal.

[10]  Dongmei Zhang,et al.  Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China-Myanmar border , 2016, Scientific Reports.

[11]  Shin-Ichiro Tachibana,et al.  Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites , 2016, Expert review of anti-infective therapy.

[12]  A. Dondorp,et al.  An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand , 2015, Scientific Reports.

[13]  A. Maji,et al.  No Polymorphism in Plasmodium falciparum K13 Propeller Gene in Clinical Isolates from Kolkata, India , 2015, Journal of pathogens.

[14]  L. Cui,et al.  Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene , 2015, Antimicrobial Agents and Chemotherapy.

[15]  Saorin Kim,et al.  Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment , 2015, Antimicrobial Agents and Chemotherapy.

[16]  Shui-sen Zhou,et al.  A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. , 2015, The Journal of infectious diseases.

[17]  S. Han,et al.  Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  R. Maude,et al.  Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker , 2015, The Lancet. Infectious diseases.

[19]  J. Barnwell,et al.  Correction: Selection and Spread of Artemisinin-Resistant Alleles in Thailand Prior to the Global Artemisinin Resistance Containment Campaign , 2015, PLoS pathogens.

[20]  John C. Tan,et al.  Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. , 2015, The Journal of infectious diseases.

[21]  Gilean McVean,et al.  Genetic architecture of artemisinin-resistant Plasmodium falciparum , 2015, Nature Genetics.

[22]  R. Haque,et al.  Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013) , 2014, Malaria Journal.

[23]  A. Rosanas-Urgell,et al.  Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam , 2014, Antimicrobial Agents and Chemotherapy.

[24]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[25]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[26]  J. Perin,et al.  Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar , 2013, PloS one.

[27]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[28]  C. Happi,et al.  Feasibility, acceptability and use of artemisinin-based combination therapy , 2010 .

[29]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[30]  A. Hubbard,et al.  Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. , 2003, The American journal of tropical medicine and hygiene.

[31]  Key Messages.  Artemisinin and artemisinin-based combination therapy resistance , 2016 .

[32]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[33]  G. Saunders.  The treatment of malaria. , 1947, Missouri medicine.